Citadel Advisors’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$369M Buy
1,869,793
+1,449,726
+345% +$280M 0.06% 251
2025
Q4
$77.2M Sell
420,067
-1,373,076
-77% -$241M 0.01% 1048
2025
Q3
$275M Buy
1,793,143
+877,671
+96% +$133M 0.04% 356
2025
Q2
$128M Sell
915,472
-107,639
-11% -$15.1M 0.02% 609
2025
Q1
$150M Sell
1,023,111
-1,088,298
-52% -$157M 0.03% 479
2024
Q4
$277M Buy
2,111,409
+1,887,183
+842% +$264M 0.05% 283
2024
Q3
$34.9M Sell
224,226
-84,628
-27% -$13.7M 0.01% 1534
2024
Q2
$48.2M Buy
308,854
+64,428
+26% +$9.7M 0.01% 1182
2024
Q1
$33.1M Buy
244,426
+29,865
+14% +$3.95M 0.01% 1565
2023
Q4
$28.9M Sell
214,561
-172,339
-45% -$22.4M 0.01% 1659
2023
Q3
$52.4M Buy
386,900
+71,201
+23% +$9.72M 0.01% 1038
2023
Q2
$45.2M Buy
315,699
+140,197
+80% +$20.6M 0.01% 1129
2023
Q1
$24.4M Buy
175,502
+17,900
+11% +$2.41M 0.01% 1731
2022
Q4
$21.4M Sell
157,602
-662,728
-81% -$83.1M 0.01% 1899
2022
Q3
$90M Buy
820,330
+813,738
+12,344% +$103M 0.02% 658
2022
Q2
$871K Sell
6,592
-2,146
-25% -$282K ﹤0.01% 7338
2022
Q1
$1.16M Sell
8,738
-579,477
-99% -$69.5M ﹤0.01% 7373
2021
Q4
$68.5M Buy
588,215
+103,029
+21% +$12.1M 0.01% 932
2021
Q3
$58.3M Sell
485,186
-131,160
-21% -$15.3M 0.01% 1008
2021
Q2
$73.8M Sell
616,346
-573,472
-48% -$62.9M 0.02% 849
2021
Q1
$118M Sell
1,189,818
-703,022
-37% -$70.7M 0.03% 512
2020
Q4
$189M Buy
1,892,840
+1,475,339
+353% +$156M 0.05% 279
2020
Q3
$45.8M Sell
417,501
-47,345
-10% -$5.27M 0.01% 917
2020
Q2
$49.2M Sell
464,846
-424,526
-48% -$43.8M 0.02% 810
2020
Q1
$79.4M Buy
889,372
+641,279
+258% +$60.4M 0.04% 430
2019
Q4
$24.7M Sell
248,093
-509,376
-67% -$48M 0.01% 1294
2019
Q3
$67.5M Buy
757,469
+113,587
+18% +$9.85M 0.03% 590
2019
Q2
$53.2M Sell
643,882
-86,202
-12% -$6.76M 0.02% 687
2019
Q1
$59M Buy
730,084
+584,498
+401% +$46.1M 0.03% 611
2018
Q4
$11.1M Sell
145,586
-1,043,266
-88% -$81.5M 0.01% 1788
2018
Q3
$94.1M Sell
1,188,852
-21,848
-2% -$1.65M 0.04% 440
2018
Q2
$85M Buy
1,210,700
+1,089,036
+895% +$78.3M 0.04% 433
2018
Q1
$8.51M Buy
121,664
+107,403
+753% +$7.44M ﹤0.01% 1889
2017
Q4
$990K Sell
14,261
-298,307
-95% -$20.1M ﹤0.01% 4671
2017
Q3
$21.2M Buy
312,568
+253,933
+433% +$16M 0.02% 1032
2017
Q2
$4M Sell
58,635
-422
-0.7% -$27.6K ﹤0.01% 2357
2017
Q1
$3.68M Sell
59,057
-178,370
-75% -$10.4M ﹤0.01% 2366
2016
Q4
$13M Buy
237,427
+83,766
+55% +$4.76M 0.01% 1168
2016
Q3
$10.1M Buy
153,661
+67,019
+77% +$4.38M 0.01% 1347
2016
Q2
$5.23M Sell
86,642
-383,317
-82% -$22.3M 0.01% 1784
2016
Q1
$26.5M Buy
+469,959
New +$28.2M 0.03% 585
2015
Q4
Sell
-159,789
Closed -$10.2M 8711
2015
Q3
$10.2M Sell
159,789
-173,913
-52% -$11.4M 0.01% 1349
2015
Q2
$21.3M Buy
333,702
+127,450
+62% +$8.73M 0.02% 959
2015
Q1
$14.1M Buy
206,252
+113,920
+123% +$7.92M 0.01% 1199
2014
Q4
$6.5M Sell
92,332
-56,371
-38% -$4.04M 0.01% 1747
2014
Q3
$10.6M Buy
148,703
+51,187
+52% +$3.75M 0.01% 1316
2014
Q2
$7.25M Buy
97,516
+87,881
+912% +$6.35M 0.01% 1528
2014
Q1
$625K Sell
9,635
-73,502
-88% -$4.75M ﹤0.01% 4035
2013
Q4
$4.94M Buy
+83,137
New +$4.52M 0.01% 1700
2013
Q3
Sell
-246,477
Closed -$11.7M 6717
2013
Q2
$11.7M Buy
+246,477
New +$12.6M 0.02% 971

Other funds holding AZN

Citadel Advisors's AZN Position: Q1 2026 in Review

Citadel Advisors increased its AstraZeneca (AZN) stake by 345% in Q1 2026, buying an estimated $280M and bringing the position to 1,869,793 shares worth $369M. The position accounts for 0.06% of the portfolio, ranked #251.

Citadel Advisors first reported a position in AZN in Q2 2013 and has held it in 50 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Citadel Advisors held 1,869,793 shares of AstraZeneca worth $369M as of Q1 2026.
  • Citadel Advisors bought 1,449,726 AstraZeneca shares in Q1 2026, an estimated $280M.
  • AstraZeneca made up 0.06% of Citadel Advisors's portfolio in Q1 2026, its #251 holding.
  • Citadel Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 50 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.